TB-500 and Thymosin Beta-4: What the Research Literature Covers

Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.

This article explains what thymosin beta-4 is, what the product called TB-500 actually contains, and what the published literature reports for each. The two are not the same molecule, and most of what is written about "TB-500" online is drawn from studies of the full-length protein. The article sorts the evidence by model system and ends with the regulatory position and what a research certificate should show.

Thymosin beta-4 is a 43-residue actin-binding protein found in nearly every cell

Thymosin beta-4 is a 43-amino-acid peptide with an acetylated N-terminus, a molecular weight near 4,963 daltons (PubChem CID 45382195), and an isoelectric point of about 5.1. Low, Hu, and Goldstein reported its complete sequence from calf thymus in a 1981 Proceedings of the National Academy of Sciences paper and, because of where it was found, classed it as a thymic hormone. That classification turned out to be a historical accident. In 1991 Safer, Elzinga, and Nachmias showed in the Journal of Biological Chemistry that an abundant actin-sequestering peptide from human platelets, which they had called Fx, was identical to thymosin beta-4. The molecule's main job is to hold actin monomers in reserve.

Huff and colleagues' 2001 review in the International Journal of Biochemistry and Cell Biology summarizes the family: beta-thymosins are small, acidic, heat-stable peptides present at high concentration in most vertebrate cells, where they bind globular actin one-to-one and prevent it from polymerizing. The sequence contains a conserved motif, Leu-Lys-Lys-Thr-Glu-Thr at residues 17 to 22, that makes direct contact with actin. Simenel and colleagues' 2000 NMR study in the European Journal of Biochemistry showed that in a membrane-mimicking solvent the peptide forms two alpha helices, one spanning residues 5 to 16 and one spanning 31 to 39, and that the LKKTET segment between them must be correctly positioned for the peptide to bind actin.

Hannappel's 2010 review in the Annals of the New York Academy of Sciences catalogs the molecule's post-translational modifications, including the N-terminal acetyl group and oxidation of methionine 6 to the sulfoxide, which a 1994 study found almost abolishes actin binding. Thymosin beta-4 is also the parent of the tetrapeptide Ac-SDKP: Kumar and colleagues showed in 2016 that two enzymes, meprin-alpha and prolyl oligopeptidase, cut the N-terminal four residues free in sequence.

TB-500 is a seven-residue fragment, not the full protein

TB-500 is the trade name under which a short synthetic fragment of thymosin beta-4 has been sold. Two doping-control laboratories characterized it independently in 2012. Esposito and colleagues, in Drug Testing and Analysis, used high-resolution Orbitrap mass spectrometry to identify the contents of a TB-500 product as the N-terminally acetylated fragment of residues 17 to 23 of human thymosin beta-4, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, and then synthesized the same peptide by solid-phase methods to confirm the match. Ho and colleagues, in the Journal of Chromatography A, reached the same conclusion for a veterinary preparation and built a method to detect the fragment and its metabolites in horse urine and plasma for equine sports testing.

The fragment has a molecular formula of C38H68N10O14 and a molecular weight of about 889 daltons (PubChem CID 62707662). It is roughly one-sixth the mass of the parent protein and contains the actin-contacting motif plus one additional glutamine. Ho and colleagues note that the product's marketing claims about cell migration and vessel growth were vendor claims, not findings of their study.

This distinction is the central fact of the topic. The LKKTET motif is necessary for actin binding, but the NMR work shows it is not sufficient: full binding requires the two flanking helices to orient the motif correctly. A seven-residue fragment cannot form those helices. Whether the fragment has any actin-sequestering activity of its own, and whether any of the parent protein's biology carries over to it, has not been established in the peer-reviewed literature.

What cell and rodent studies report for the full-length protein

The preclinical literature on thymosin beta-4 is large and comes from many independent groups. Malinda and colleagues, in a 1999 Journal of Investigative Dermatology paper, reported that the peptide increased re-epithelialization and collagen deposition in a rat full-thickness wound model and stimulated keratinocyte migration in a Boyden chamber at picogram amounts. Sosne and colleagues reported in Experimental Eye Research in 2002 that it accelerated corneal re-epithelialization and reduced inflammatory cell infiltration in mice after alkali injury.

The cardiac work is the most cited. Bock-Marquette and colleagues, in Nature in 2004, showed that thymosin beta-4 promoted migration and survival of embryonic and postnatal cardiomyocytes in culture, that it formed a complex with PINCH and integrin-linked kinase leading to Akt activation, and that it improved cardiac function in mice after coronary artery ligation. Smart and colleagues, also in Nature, reported in 2007 that the peptide is required for coronary vessel development in mouse embryos and can mobilize adult epicardial cells into vascular lineages, and in 2011 that priming mice with the peptide before injury allowed epicardium-derived progenitors to give rise to new cardiomyocytes. Both Nature papers emphasized that the effect depended on timing and on the full-length molecule.

Goldstein, Hannappel, and Kleinman's 2005 review in Trends in Molecular Medicine and Crockford and colleagues' 2010 review collect these and many other studies. The common thread is actin: by changing the pool of free actin monomers, the peptide alters cell migration, adhesion, and survival signaling. Every study in this section used the 43-residue molecule, usually produced by solid-phase synthesis or recombinant expression, and none used the seven-residue fragment.

Human trials exist for thymosin beta-4, and none for the fragment

Full-length thymosin beta-4 has reached controlled human trials under the development code RGN-259 and related programs. Sosne, Dunn, and Kim reported in Cornea in 2015 a small, multicenter, randomized, double-masked, placebo-controlled phase 2 trial of thymosin beta-4 eye drops in nine participants with severe dry eye; the RGN-259 group showed a 35 percent reduction in ocular discomfort and a 59 percent reduction in corneal fluorescein staining relative to vehicle at day 56. A companion 2015 trial by Sosne and Ousler used a controlled adverse environment model. Guarnera and colleagues described in 2007 the design of a European randomized, placebo-controlled, escalating-level study of topical thymosin beta-4 in venous ulcers across ten sites in Italy and Poland.

These trials are small, and the compound remains investigational: thymosin beta-4 is not an approved drug in the United States or elsewhere. They are nonetheless real controlled human data, which the fragment entirely lacks. The FDA's list of bulk substances nominated for compounding names "thymosin beta-4 fragment (LKKTETQ), also known as TB-500" among substances that were nominated and withdrawn, and records that the agency identified no human exposure data for it. No clinical trial of Ac-LKKTETQ is registered or published, and the only peer-reviewed papers that name TB-500 are the analytical and doping-control studies described above.

A reader who sees "TB-500 research" cited for a wound, cardiac, or corneal finding should check which molecule the paper used; in nearly every case it is the 43-residue protein.

What is established and what is not

For thymosin beta-4, the following are established across multiple groups: the sequence and mass; one-to-one actin monomer binding that inhibits polymerization; the two-helix solution structure and the LKKTET contact motif; migration and survival responses in several cultured cell types; faster re-epithelialization in rodent skin and corneal models; cardiac repair findings in mice after coronary ligation; and small controlled human trials in dry eye and venous ulcers. Not established: any approved use; durable efficacy in large trials; and the mechanism by which an extracellular peptide whose known function is intracellular produces the reported effects, which the reviews describe as an open question.

For the Ac-LKKTETQ fragment, the following are established: its identity in commercial TB-500 products by high-resolution mass spectrometry; its synthesis by solid-phase methods; and analytical methods for detecting it and its metabolites. Not established: actin binding of comparable affinity to the parent protein; any cell-culture result reported by an independent group; any rodent result; and any human data at all. The honest summary is that TB-500 is an analytically well-characterized chemical with almost no published biology of its own.

An actin polymerization assay using pyrene-labeled actin can test directly whether the fragment sequesters monomers, a question the literature has left open. A certificate for the fragment should show identity by mass spectrometry with an observed mass consistent with 889 daltons, purity by HPLC, and net peptide content, because a short, basic sequence with two lysines carries a proportionally large counter-ion load. The TB-500 5 mg, TB-500 10 mg, and TB-500 15 mg listings each carry a lot-matched certificate so that a buyer can check the identity and content lines before purchase.

Naming, regulatory status, and reading a certificate

The naming confusion has a simple source. "Thymosin beta-4" is the protein. "TB-500" is a trade name for the fragment, borrowed informally for the protein by vendors and by some writers. "Tβ4" and "TB4" are abbreviations for the protein. "RGN-259" is a development code for a formulation of the protein. "Ac-SDKP" is a different fragment altogether, the first four residues, released enzymatically in vivo. Our article on why one peptide has five names uses this family as a worked example, and BPC-157 vs TB-500 compares the fragment with its most common blend partner.

Neither molecule is an approved drug anywhere; the protein is in clinical development and the fragment is not. In sport, Ho and colleagues' paper documents that the fragment was already a doping-control target in equine racing by 2012.

When reading a certificate, the identity line is the one that settles the question of which molecule is in the vial. A mass near 889 daltons is the fragment; a mass near 4,963 daltons is the protein. The two are not interchangeable, and a certificate that reports purity without an observed mass has not told the buyer which one it is. How the mass spectrum establishes identity is covered in LC-MS identity confirmation.

Frequently Asked Questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue actin-binding protein. TB-500 is a trade name for a seven-residue synthetic fragment, Ac-LKKTETQ, corresponding to residues 17 to 23 of the protein, identified by two doping-control laboratories in 2012. Nearly all published biology concerns the full protein.

What does thymosin beta-4 do in cells?

It binds globular actin one-to-one and prevents it from polymerizing, which makes it the main actin-sequestering molecule in most vertebrate cells. In culture it has been reported to increase migration and survival of several cell types, including keratinocytes, endothelial cells, and cardiomyocytes.

Has TB-500 been tested in humans?

No published or registered clinical trial of the Ac-LKKTETQ fragment exists, and the FDA records no identified human exposure data for it. Small controlled trials exist for the full-length protein in dry eye and venous ulcers, but those results belong to the 43-residue molecule, not the fragment.

Is thymosin beta-4 or TB-500 approved by the FDA?

Neither is an approved drug in the United States or any other country. Full-length thymosin beta-4 has been in clinical development under codes such as RGN-259. The FDA lists the LKKTETQ fragment among compounding nominations it declined to permit, citing the absence of human safety data.

Citations

1. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981;78(2):1162-1166. PMID 6940133
2. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID 1999398
3. Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. PMID 11311852
4. Simenel C, Van Troys M, Vandekerckhove J, Ampe C, Delepierre M. Structural requirements for thymosin beta4 in its contact with actin. An NMR-analysis of thymosin beta4 mutants in solution and correlation with their biological activity. Eur J Biochem. 2000;267(12):3530-3538. PMID 10848969
5. Hannappel E. Thymosin beta4 and its posttranslational modifications. Ann N Y Acad Sci. 2010;1194:27-35. PMID 20536447
6. Heintz D, Reichert A, Mihelic-Rapp M, et al. The sulfoxide of thymosin beta 4 almost lacks the polymerization-inhibiting capacity for actin. Eur J Biochem. 1994;223(2):345-350. PMID 8055902
7. Kumar N, Nakagawa P, Janic B, et al. The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase. Am J Physiol Renal Physiol. 2016;310(10):F1026-F1034. PMID 26962108
8. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. PMID 22962027
9. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PMID 23084823
10. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PMID 10469335
11. Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299. PMID 11950239
12. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID 15565145
13. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PMID 17108969
14. Smart N, Bollini S, Dubé KN, et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011;474(7353):640-644. PMID 21654746
15. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. PMID 16099219
16. Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. PMID 20536467
17. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. PMID 25826322
18. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015;9:877-884. PMID 26056426
19. Guarnera G, De Rosa A, Camerini R. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci. 2007;1112:407-412. PMID 17495250
20. PubChem. Thymosin beta-4, CID 45382195. National Library of Medicine. pubchem.ncbi.nlm.nih.gov
21. PubChem. TB-500 (Ac-LKKTETQ), CID 62707662. National Library of Medicine. pubchem.ncbi.nlm.nih.gov
22. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov

This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.

Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.